The CDI is comprised of more than two dozen accomplished faculty members who have been recruited from leading academic centers including Weill Cornell Medicine, Columbia University, Albert Einstein College of Medicine, the University of Iowa, Temple University, Boston University, Rutgers University, Memorial Sloan Kettering Cancer Center and the National Institutes of Health. Areas of expertise include genomics, epigenetics, drug resistance, stem cell biology, drug discovery, diagnostics, vaccines and pharmacology. These areas confront critical unmet needs in targeting hematologic malignancies including multiple myeloma and lymphoma, breast cancer, brain tumors and other deadly cancers, as well as addressing crucial medical problems including graft versus host disease, inflammatory diseases, diabetes, sepsis, and COVID-19, bacterial, fungal and other viral infections. In total, the inaugural faculty have published more than 2,000 peer-reviewed papers in leading journals such as Science and Nature, New England Journal of Medicine, mBio and Lancet. In addition, they bring approximately 57 total NIH awards and other government grants to the CDI, as well as numerous contracts with foundations, Pharma and biotech companies.
Affiliated and Emeritus Faculty
Postdoctoral researchers comprise a vital aspect of the CDI research enterprise. The highly collaborative culture of discovery provides an outstanding training experience in which intellectual curiosity and interdisciplinary teamwork is encouraged and nurtured.
Postdocs have access to a variety of training resources to acquire new skills that facilitate career development. Mentoring is provided for development of grants and contracts, manuscript preparation, poster and research presentations, and research ethics, and science management. Furthermore, postdocs are exposed to a range of external basic and translational academic scientists, as well as industry leaders. The collective experience will help position them for a successful job search and career path.